Aliskiren and valsartan combination therapy for the management of hypertension

References

• GilesTDMatersonBJCohnJNKostisJBDefinition and classification of hypertension: an updateJ Clin Hypertens (Greenwich)2009111161161419878368
   PubMed Web of Science ®Google Scholar
• LewingtonSClarkeRQizilbashNPetoRCollinsRAge-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesLancet200236093491903191312493255
   PubMed Web of Science ®Google Scholar
• VasanRSLarsonMGLeipEPImpact of high-normal blood pressure on the risk of cardiovascular diseaseN Engl J Med2001345181291129711794147
   PubMed Web of Science ®Google Scholar
• DouglasJGBakrisGLEpsteinMManagement of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in BlacksArch Intern Med2003163552554112622600
   PubMedGoogle Scholar
• ChobanianAVBakrisGLBlackHRSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension20034261206125214656957
   PubMed Web of Science ®Google Scholar
• OngKLCheungBMManYBLauCPLamKSPrevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004Hypertension2007491697517159087
   PubMed Web of Science ®Google Scholar
• WongNDLopezVAL‘ItalienGChenRKlineSEFranklinSSInadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003–2004Arch Intern Med2007167222431243618071164
   PubMedGoogle Scholar
• CushmanWCFordCECutlerJASuccess and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)J Clin Hypertens (Greenwich)20024639340412461301
   PubMedGoogle Scholar
• DahlöfBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet2005366948989590616154016
   PubMed Web of Science ®Google Scholar
• WrightJTJrBakrisGGreeneTEffect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trialJAMA2002288192421243112435255
   PubMed Web of Science ®Google Scholar
• ManciaGLaurentSAgabiti-RoseiEReappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documentJ Hypertens2009272121215819838131
   PubMed Web of Science ®Google Scholar
• KjeldsenSEWeberMOparilSJamersonKACombining RAAS and calcium channel blockade: ACCOMPLISH in perspectiveBlood Press2008175–626026919061055
   PubMed Web of Science ®Google Scholar
• JamersonKWeberMABakrisGLBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med2008359232417242819052124
   PubMed Web of Science ®Google Scholar
• WeberMAJuliusSKjeldsenSEBlood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE TrialLancet200436394262049205115207957
   PubMed Web of Science ®Google Scholar
• StaessenJAThijisqLFagardREffects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe TrialJ Hypertens200422484785715126928
   PubMed Web of Science ®Google Scholar
• DzauVJAntmanEMBlackHRThe cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease)Circulation2006114252850287017179034
   PubMed Web of Science ®Google Scholar
• DzauVJTheodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesisHypertension20013741047105211304501
   PubMed Web of Science ®Google Scholar
• SchmitzOHansenHEOrskovHMogensenCEPosborg PetersenVEnd-state renal failure in diabetic nephropathy: pathophysiology and treatmentBlood Purif198531–31201393913447
   PubMedGoogle Scholar
• BrennerBMCooperMEde ZeeuwDEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathyN Engl J Med20013451286186911565518
   PubMed Web of Science ®Google Scholar
• ParvingHHPerssonFLewisJBLewisEJHollenbergNKAliskiren combined with losartan in type 2 diabetes and nephropathyN Engl J Med2008358232433244618525041
   PubMed Web of Science ®Google Scholar
• AldermanMHOoiWLCohenHMadhavanSSealeyJELaraghJHPlasma renin activity: a risk factor for myocardial infarction in hypertensive patientsAm J Hypertens1997101189008242
   PubMed Web of Science ®Google Scholar
• VermaSGuptaMHolmesDT2009Plasma renin activity is associated with increased cardiovascular events and mortality in the HOPE studyCirculation120S453 Abstract 1134.
   Google Scholar
• BairTLMayHTPrescottMF2009Association between baseline levels of plasma renin activity and risk of cardiovascular eventsJ Am Coll Cardiol5310 Suppl AA383 Abstract 1028–12.
   Web of Science ®Google Scholar
• VogtBBurnierMAldosterone and cardiovascular riskCurr Hypertens Rep200911645045519895757
   PubMed Web of Science ®Google Scholar
• DoultonTWACE inhibitor-angiotensin receptor blocker combinations: a clinician’s perspectiveMini Rev Med Chem20066549149716719821
   PubMed Web of Science ®Google Scholar
• EpsteinBJSmithSMChoksiRRecent changes in the landscape of combination RAS blockadeExpert Rev Cardiovasc Ther20097111373138419900020
   PubMedGoogle Scholar
• YonedaTTakedaYUsukuraMAldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitusAm J Hypertens200720121329133318047925
   PubMed Web of Science ®Google Scholar
• BombackASKlemmerPJThe incidence and implications of aldosterone breakthroughNat Clin Pract Nephrol20073948649217717561
   PubMedGoogle Scholar
• RiccioniGVitulanoND’OrazioNBellocciFAliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertensionAdv Ther200926770071019649581
   PubMed Web of Science ®Google Scholar
• DoultonTWHeFJMacGregorGASystematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertensionHypertension200545588088615809363
   PubMed Web of Science ®Google Scholar
• YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• MannJFSchmiederREMcQueenMRenal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trialLancet2008372963854755318707986
   PubMed Web of Science ®Google Scholar
• HollenbergNKParvingHHVibertiGAlbuminuria response to very high-dose valsartan in type 2 diabetes mellitusJ Hypertens20072591921192617762658
   PubMed Web of Science ®Google Scholar
• AtlasSAThe renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibitionJ Manag Care Pharm2007138 Suppl S-bS9S2017605505
   PubMed Web of Science ®Google Scholar
• RouleauJLPackerMMoyeLPrognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captoprilJ Am Coll Cardiol19942435835917915733
   PubMed Web of Science ®Google Scholar
• LatiniRMassonSAnandIThe comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFTEur Heart J200425429229914984917
   PubMed Web of Science ®Google Scholar
• O‘BrienEBartonJNussbergerJAliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blockerHypertension200749227628417159081
   PubMed Web of Science ®Google Scholar
• UresinYTaylorAAKiloCEfficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertensionJ Renin Angiotensin Aldosterone Syst20078419019818205098
   PubMed Web of Science ®Google Scholar
• FisherNDJan DanserAHNussbergerJDoleWPHollenbergNKRenal and hormonal responses to direct renin inhibition with aliskiren in healthy humansCirculation2008117253199320518559696
   PubMed Web of Science ®Google Scholar
• PerssonFRossingPReinhardHRenal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuriaDiabetes Care200932101873187919587362
   PubMed Web of Science ®Google Scholar
• McMurrayJJPittBLatiniREffects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failureCirc Heart Fail20081172419808266
   PubMed Web of Science ®Google Scholar
• SolomonSDAppelbaumEManningWJEffect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophyCirculation2009119453053719153265
   PubMed Web of Science ®Google Scholar
• TaylorAAAndersonDRAroraV2007Renin system suppression with the oral direct renin inhibitor aliskiren administered alone or in combination: a pooled analysis of 1093 patients with hypertensionJ Am Coll Cardiol499 Suppl A370A Abstract 1014–1170.
   Web of Science ®Google Scholar
• AziziMMénardJBisseryAPharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruptionJ Am Soc Nephrol200415123126313315579516
   PubMed Web of Science ®Google Scholar
• AndersenKWeinbergerMHConstanceCCComparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertensionJ Renin Angiotensin Aldosterone Syst200910315716719617271
   PubMed Web of Science ®Google Scholar
• Valturna (aliskiren and valsartan, USP) Tablets [prescribing information]2010East Hanover, NJNovartis Pharmaceuticals Corporation
   Google Scholar
• OparilSYarowsSAPatelSFangHZhangJSatlinAEfficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trialLancet2007370958322122917658393
   PubMed Web of Science ®Google Scholar
• YarowsSAOparilSPatelSFangHZhangJAliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind studyAdv Ther200825121288130219066757
   PubMed Web of Science ®Google Scholar
• ChrysantSGMurrayAVHoppeUCLong-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysisCurr Med Res Opin20082441039104718307835
   PubMed Web of Science ®Google Scholar
• PoolJLSchmiederREAziziMAliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartanAm J Hypertens2007201112017198906
   PubMed Web of Science ®Google Scholar
• BangaloreSKamalakkannanGParkarSMesserliFHFixed-dose combinations improve medication compliance: a meta-analysisAm J Med2007120871371917679131
   PubMed Web of Science ®Google Scholar
• BurnierMBrownREOngSHKeskinaslanAKhanZMIssues in blood pressure control and the potential role of single-pill combination therapiesInt J Clin Pract200963579079819220523
   PubMed Web of Science ®Google Scholar
• RicheDMMinorDSHoldinessASEastHEAn issue of dependence: implications from the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trialJ Clin Hypertens (Greenwich)2009112899319222674
   PubMed Web of Science ®Google Scholar
• PittBRemmeWZannadFEplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctionN Engl J Med2003348141309132112668699
   PubMed Web of Science ®Google Scholar
• PittBZannadFRemmeWJThe effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study InvestigatorsN Engl J Med19993411070971710471456
   PubMed Web of Science ®Google Scholar
• BauersachsJHeckMFraccarolloDAddition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expressionJ Am Coll Cardiol200239235135811788231
   PubMed Web of Science ®Google Scholar
• RajagopalanSDuquaineDKingSPittBPatelPMineralocorticoid receptor antagonism in experimental atherosclerosisCirculation2002105182212221611994257
   PubMed Web of Science ®Google Scholar
• ParvingHHBrennerBMMcMurrayJJAliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study designNephrol Dial Transplant20092451663167119145003
   PubMed Web of Science ®Google Scholar
• LeeHYOhBHCardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER programExpert Rev Cardiovasc Ther20097325125719296761
   PubMedGoogle Scholar
• LorigaGVidiliGRuggenentiPFaeddaRSannaMSattaAERenal hemodynamics and renoprotectionNephron Clin Pract20081104c213c21918974652
   PubMedGoogle Scholar
• DrummondWMungerMARafiqueEMMaboudianMKhanMKeefeDLAntihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapyJ Clin Hypertens (Greenwich)200791074275017917501
   PubMedGoogle Scholar
• VillamilAChrysantSGCalhounDRenin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazideJ Hypertens200725121722617143194
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJBoschJDaviesRDagenaisGEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med2000342314515310639539
   PubMed Web of Science ®Google Scholar
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study GroupN Engl J Med198731623142914352883575
   PubMed Web of Science ®Google Scholar
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD InvestigatorsN Engl J Med199132552933022057034
   PubMed Web of Science ®Google Scholar
• CohnJNTognoniGA randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failureN Engl J Med2001345231667167511759645
   PubMed Web of Science ®Google Scholar
• DahlöfBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialLancet2003362938677277613678870
   PubMed Web of Science ®Google Scholar
• LewisEJHunsickerLGClarkeWRRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetesN Engl J Med20013451285186011565517
   PubMed Web of Science ®Google Scholar
• PfefferMAMcMurrayJJVelazquezEJValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or bothN Engl J Med2003349201893190614610160
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet2003362938676777113678869
   PubMed Web of Science ®Google Scholar
• MogensenCENeldamSTikkanenIRandomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) studyBMJ200032172741440144411110735
   PubMed Web of Science ®Google Scholar
• BakrisGLRuilopeLLocatelliFTreatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trialKidney Int200772787988517667984
   PubMed Web of Science ®Google Scholar